Drugs / Anrotenib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04229849 | Jan 2020 → Jan 2021 | esophageal squamous cell carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anrotenib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04229849 ↗ |
| Route | Oral | “Anrotenib: 10 mg on day 1-14 orally repeated every 21 days” NCT04229849 ↗ |